Tumour treating fields in a combinational therapeutic approach.
Tumour treating fields in a combinational therapeutic approach.
复制标题
DOI：
10.18632/oncotarget.26344
复制
发表时间：
2018-11-27
期刊：
影响因子：
--
通讯作者：
Smith, Stuart
中科院分区：
文献类型：
--
作者：
Branter, Joshua;Basu, Surajit;Smith, Stuart
自 2005 年以来，新诊断的多形性胶质母细胞瘤 (GBM) 患者的护理标准一直保持不变，患者接受最大程度的手术切除，然后进行放疗以及替莫唑胺的伴随和维持治疗。最近，在 EF-11 和 EF-14 试验之后，肿瘤治疗领域 (TTFields) 疗法已分别获得 FDA 批准用于成人复发性和成人新诊断的 GBM。 TTFields 是一种非侵入性抗癌治疗方法，利用中频交变电场来靶向活跃分裂的癌细胞。 TTFields 通过与关键有丝分裂蛋白相互作用，选择性地靶向有丝分裂内的细胞，导致有丝分裂停滞和细胞死亡。由于缺乏与电场相关的重叠毒性，TTFields 疗法成为联合治疗途径的候选者。在这里，我们回顾了有关 TTFields 与烷化剂、放射、抗血管生成药物、有丝分裂抑制剂、免疫疗法以及新药物联合使用的最新文献。这篇综述强调了观察到的 TTFields 与各种其他疗法相结合的协同和相加效应，并强调了与电场组合相关的策略。
The standard of care for patients with newly diagnosed Glioblastoma multiforme (GBM) has remained unchanged since 2005, with patients undergoing maximal surgical resection, followed by radiotherapy plus concomitant and maintenance Temozolomide. More recently, Tumour treating fields (TTFields) therapy has become FDA approved for adult recurrent and adult newly-diagnosed GBM following the EF-11 and EF-14 trials, respectively. TTFields is a non-invasive anticancer treatment which utilizes medium frequency alternating electric fields to target actively dividing cancerous cells. TTFields selectively targets cells within mitosis through interacting with key mitotic proteins to cause mitotic arrest and cell death. TTFields therapy presents itself as a candidate for the combinational therapy route due to the lack of overlapping toxicities associated with electric fields. Here we review current literature pertaining to TTFields in combination with alkylating agents, radiation, anti-angiogenics, mitotic inhibitors, immunotherapies, and also with novel agents. This review highlights the observed synergistic and additive effects of combining TTFields with various other therapies, as well highlighting the strategies relating to combinations with electric fields.